CR

ALLOSOURCE ANNOUNCES POSTER FEATURING PROCHONDRIX CR OSTEOCHONDRAL ALLOGRAFT CLINICAL OUTCOMES AT THE 17TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY (ICRS) WORLD CONGRESS

Retrieved on: 
Friday, September 8, 2023
Science, Surgeon, Treatment, New product development, Data collection, Cartilage, ICRS, Research, Osteoarthritis, Innovation, Patella, Knee, Patient, Physician, CR, World Congress, Maintenance (technical)

ProChondrix CR Cryopreserved Osteochondral Allograft is a single-stage, cryopreserved, articular cartilage allograft.

Key Points: 
  • ProChondrix CR Cryopreserved Osteochondral Allograft is a single-stage, cryopreserved, articular cartilage allograft.
  • The poster titled, "ProChondrix® CR Prospective Clinical Outcomes for the Repair of Focal Articular Cartilage Defects in the Knee" evaluates the prospective clinical outcomes of patients who received ProChondrix CR in focal cartilage lesions of the patella and femoral condyle of the knee.
  • "This ICRS poster showcases the promising results surgeons are having treating their patients with ProChondrix CR," said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Affairs.
  • For additional detail on ProChondrix CR's clinical outcomes visit the ICRS poster showcase or E-Poster online #208.

NaaS Records 132% YoY Revenue Growth and 112% YoY Increase of Charging Volume reaching 2,251 GWh in H1 2023

Retrieved on: 
Friday, September 8, 2023
EV, NAAS, Network as a service, SEK, USD, PICC, US, Fortune 500, Hyundai, Kilowatt-hour, Invesco, CR, Ecosystem, RMB, Cryptocurrency, Renewable energy

Charging volume transacted through NaaS' network reached 1,228 GWh in the second quarter of 2023 and 2,251 GWh in the first half of 2023, representing an increase of 112% and 112% year over year, respectively.

Key Points: 
  • Charging volume transacted through NaaS' network reached 1,228 GWh in the second quarter of 2023 and 2,251 GWh in the first half of 2023, representing an increase of 112% and 112% year over year, respectively.
  • Non-IFRS net loss attributable to ordinary shareholders increased by 12% year over year to RMB108.0 million (US$14.9 million) in the second quarter of 2023.
  • Invesco WilderHill Clean Energy ETF, a subsidiary of global asset management magnate Invesco Ltd., has a large position of NaaS stock.
  • In the second quarter, 53.4% of NaaS' revenue goes to its offline and innovative services, achieving an unprecedented ratio of over 50%.

Steele Honda Expands Its Lineup with the Arrival of the 2024 Honda CR-V

Retrieved on: 
Thursday, September 7, 2023
Safety, Kenmount Road, CR-V, Multimedia, Continuously variable transmission, SUV, Honda, CR, NL, CVT, Automotive industry, Road

ST. JOHN'S, Newfoundland, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Steele Honda, a beacon of automotive excellence in the heart of Texas, proudly announces the latest addition to its stellar lineup—the 2024 Honda CR-V. With its captivating design, spirited performance, inviting interior, Honda Sensing® and cutting-edge technology, this SUV is poised to redefine the driving experience.

Key Points: 
  • St. John's customers looking for an SUV must check out the latest 2024 Honda CR-V at the Steele Honda dealership.
  • The 2024 Honda CR-V, a true visual delight, boasts a streamlined design.
  • Customers are encouraged to drop by the Steele Honda dealership located at 547 Kenmount Road, St. John's, NL A1B 4J8.
  • Drivers can also schedule a test drive of the 2024 Honda CR-V online and contact the friendly and knowledgeable dealership staff at 709-579-1999 for further information.

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Retrieved on: 
Thursday, August 31, 2023
Bevacizumab, Senior, ADCC, Neoplasm, Lead, Head, Bioinformatics, GAAP, Information technology, Doctor of Philosophy, Patient, HNSCC, ADCP, Research and development, R, HCC, SAB, CD47, PRS, Therapy, Merck & Co., Net, Cervical cancer, CPS, MSI, ADC, PD-1, PR, Safety, Exercise, AACR, Liver disease, MSS, Roche, Therapeutic index, GenScript Biotech, American Association for Cancer Research, CR, Pembrolizumab, ORR, Renal cell carcinoma, SCC, CRC, RCC, ADS, CMC, Yan Li, Clinical trial, Trae Waynes, Endometrial cancer, Financial toxicity, Poster, Tumor microenvironment, Pharmaceutical industry, Palladium, Medical imaging, Vaccine, Management, Cryptocurrency, Fine chemical, Bank, Legend, Immunoglobulin G, MD, Sanofi, Exelixis

Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.

Key Points: 
  • Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.
  • Cash and cash equivalents were US$128.8 million as of June 30, 2023, compared to US$143.8 million as of December 31, 2022.
  • The company uses non-GAAP net loss and non-GAAP net loss per ordinary shares for the period, which are non-GAAP financial measures, in evaluating its operating results and for financial and operational decision-making purposes.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Drivers Can Purchase the 2024 Honda CR-V EX AWD in Meridian, Mississippi

Retrieved on: 
Tuesday, August 29, 2023
CR, Traction, AWD, Android, Multimedia, Atmosphere, Honda, Safety, SUV, Rail transport, Online shopping

MERIDIAN, Miss., Aug. 29, 2023 /PRNewswire-PRWeb/ -- Drivers in Meridian, Mississippi, can now elevate their driving adventures with the 2024 Honda CR-V EX AWD available at Meridian Honda. This exceptional vehicle is set to revolutionize the driving experience, boasting a blend of style, performance, and cutting-edge features.

Key Points: 
  • MERIDIAN, Miss., Aug. 29, 2023 /PRNewswire-PRWeb/ -- Drivers in Meridian, Mississippi, can now elevate their driving adventures with the 2024 Honda CR-V EX AWD available at Meridian Honda.
  • The 2024 Honda CR-V EX AWD offers a fusion of modern design and innovative technology, making it a standout in its class.
  • With its sleek exterior lines and bold front grille, the CR-V EX AWD exudes an air of sophistication while maintaining its rugged capabilities.
  • Equipped with all-wheel drive (AWD), this vehicle ensures optimum traction and stability, especially on challenging terrains, promising a confident journey on every road.

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

Retrieved on: 
Tuesday, August 29, 2023
Faron Pharmaceuticals, MCR, Survival, HMA, Bone marrow, Head, MBA, Congress, Nasdaq First North, Patient, MedRxiv, Majesty of the Seas, Executive, AIM, European Hematology Association, NK, Manuscript, Celgene, ORS, PD-1, FDA, IPF, Venetoclax, ODD, Cancer, American Association for Cancer Research, Immunotherapy, Antigen presentation, Biomarker, CR, Tuomo, Bristol Myers Squibb, MDS, EUR, AML, Azacitidine, CPA, Tumor microenvironment, Lithium, Pharmaceutical industry, Vaccine, Management, Security (finance), Rare-earth element, Medical imaging, Fårö, Phase, SOC

TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").

Key Points: 
  • Mr. Leopoldo Zambeletti stepped down from the Board to assume a business development consulting role at Faron.
  • TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").
  • "I am extremely proud of the progress we made in the first half of 2023,” said Dr. Markku Jalkanen, Chief Executive Officer of Faron.
  • On June 30, 2023, the Company had outstanding borrowings of EUR 9.8 million under a loan facility with IPF Partners which is subject to financial covenants.

NewLink and NaaS Reach Strategic Partnership with CR Capital MGMT to Accelerate New Energy Infrastructure Development

Retrieved on: 
Friday, August 25, 2023
Semiconductor, Partnership, EV, China Resources, Information technology, Industrialisation, NAAS, Biotechnology, CNY, Network as a service, Carbon, EVS, CR, Ecosystem, Cryptocurrency, Renewable energy

By expanding the scope of new energy business scenarios, this collaborative endeavor promises to invigorate green and low-carbon energy development.

Key Points: 
  • By expanding the scope of new energy business scenarios, this collaborative endeavor promises to invigorate green and low-carbon energy development.
  • Qin Feng, General Manager and CEO of CR Capital MGMT stated, “CR Capital MGMT upholds the mission to incubate emerging industries and support industrial development, actively exploring the investment and ecosystem construction of strategic emerging industries.
  • Wang Yang, Co-founder and President of NewLink, Founder and CEO of NaaS, praised CR Capital MGMT’s strategic vision in advancing renewable energy transformation and low-carbon evolution of the energy landscape.
  • “We expect to work with CR Capital MGMT to drive the digital and intelligent upgrade of energy infrastructure.

AMD Showcases How Innovation and Partnerships Advance Corporate Responsibility

Retrieved on: 
Thursday, August 24, 2023
Semiconductor, Task force, Education, Corporate social responsibility, Sustainability Accounting Standards Board, AMD, Culture, University, Woman, GHG, Research, Materiality, TCFD, Sustainability accounting, Climate change, GRI, HPC, Engineering, Corporation, CR, Artificial intelligence, ESG, AI, Environment, Corporate responsibility, Female, Responsibility, Cryptocurrency, Management, STEM

SANTA CLARA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today released its annual Corporate Responsibility (CR) Report, detailing progress toward goals spanning environmental sustainability ; digital impact ; supply chain responsibility ; and diversity, belonging and inclusion .

Key Points: 
  • SANTA CLARA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today released its annual Corporate Responsibility (CR) Report, detailing progress toward goals spanning environmental sustainability ; digital impact ; supply chain responsibility ; and diversity, belonging and inclusion .
  • “At AMD, Corporate Responsibility is an integral part of our business strategy, culture and the relationships we foster with our customers and partners,” said Susan Moore, corporate vice president of Corporate Responsibility and International Government Affairs at AMD and president of the AMD Foundation.
  • Responsible artificial intelligence (AI) and product use emerged as new issues with high impact on both AMD and society.
  • AMD prepared the 2022-23 Corporate Responsibility Report in accordance with the Global Reporting Initiative (GRI) Standards (2021).

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Thursday, August 24, 2023
CRC, CR, CRi, Clinical trial, FLT3, AML, CRP, Patient, Symantec Endpoint Protection, CRH, Pharmaceutical industry

Among the ten (10) evaluable patients, nine (9) had failed prior venetoclax treatment (Prior-VEN), representing an emerging population with severe unmet medical need.

Key Points: 
  • Among the ten (10) evaluable patients, nine (9) had failed prior venetoclax treatment (Prior-VEN), representing an emerging population with severe unmet medical need.
  • Four (4) of the nine (9) Prior-VEN failure patients had already achieved responses with TUS/VEN (44% CRc).
  • Additionally, two (2) of three (3) patients with mutated FLT3 (67%) achieved responses.
  • Importantly, The TUS/VEN combination continues to be safe and well tolerated.

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, DNA, Auckland City Hospital, Electroporation, Radiation, Circulating tumor DNA, University, PPM, Chief Justice of Hungary, Aes, Liquid biopsy, Cancer, Hope, Medicine, Doctor of Philosophy, Șaeș, MRD, NeXT, MRI, CD8, Patient, Sorafenib, EP, Immune system, CR, Cancer vaccine, Liver, CRS, Neoplasm, HCC, CMR, PD-1, Oncology, Pembrolizumab, Recurrence, SD, PR, Safety, Biopsy, Pharmaceutical industry, Medical imaging, Geneo Grissom

PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose liver and lung lesions shrank to become fully responsive to surgery and radiation (secondary resectability).

Key Points: 
  • Geneos reports today that four additional patients have achieved a complete molecular response (CMR) by ultrasensitive, third-generation, circulating tumor DNA (ctDNA) analysis.
  • By RECIST1.1, three of these four patients are durable partial responses (PR) and one a durable stable disease (SD).
  • By either RECIST1.1 or by ctDNA response, 11 of 32 evaluable have achieved either a complete response, partial response, or complete molecular response.
  • Cancer vaccines based on our DNA vaccine platform are showing complete responses in patients with late-stage, advanced cancer.